Drug intelligence / Profile preview

MPH-S

Development stage: Preclinical
Lead developer: Motric Bio
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

MPH-S is a preclinical-stage small molecule drug candidate developed by Motorpharma. It is designed to target smooth muscle myosin to modulate smooth muscle function, with the primary therapeutic objective of aiding recovery following an ischemic stroke. By targeting the contractile machinery of smooth muscle cells, MPH-S aims to improve physiological outcomes and facilitate rehabilitation in the post-stroke period. The drug is currently undergoing preclinical evaluation to establish its efficacy and safety profile for stroke recovery applications.

Targets

Skeletal muscle myosin (SkM-Myosin)

Beyond the preview

Go deeper on MPH-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPH-S.

Explore the full profile